

JUSWINDER SINGH

singhjus@yahoo.com
8 Metcalf lane
Southborough, MA01772
781-654-6183



PROFESSIONAL SUMMARY

- Entrepreneur and innovator
- Expert in the area of rational drug design of both small molecules and protein therapeutics
- Proven record in drug discovery with experience in developing novel methodologies
- Experienced manager of research teams

KEY ACHIEVEMENTS

- Founded Avila Therapeutics in 2006 (Sold to Celgene for \$350 million in 2012)
- Advanced multiple NCEs into clinical development including CO1686 which was designated Breakthrough status by FDA in May2014 for addressing drug resistance in lung cancer
- Entrepreneur who has raised over \$50million in venture capital. Winner of 2013 New England Venture Capital Award
- Formed alliances with Novartis, Sanofi-Aventis, Clovis Oncology, National Institute of Allergy and Infectious Diseases and Leukemia and Lymphoma Society
- Innovator in the area of rational drug design with over 65 publications and one book. Cited over 3000 times

EMPLOYMENT HISTORY

2014	Jusnewco	Southborough MA
2012-2013	Celgene Avilomics Research (A Celgene company) Distinguished Investigator (The highest scientific level within Celgene)	Bedford, MA
2006-2012	Avila Therapeutics (Formerly Conxcys Inc) Co-Founder and CSO	Bedford, MA
2005-2006	Conxcys Inc President and founder	Ashland, MA
1994-2005	Biogen Idec Director of Structural Informatics	Cambridge, MA
1991-1994	Parke-Davis Senior Scientist	Ann Arbor MI

EDUCATION, AFFILIATIONS, AND PUBLICATIONS

University College London (Dame Janet Thornton F.R.S.) London, England
Post-doc., Computer-based drug design

Birkbeck College/Pfizer (Sir T.L. Blundell F.R.S., Simon Campbell F.R.S. and Dame Janet Thornton F.R.S.)

PhD, Computer-based drug design

Sussex University

B.Sc, Biochemistry (First Class Honors)

Chemical Biology and Drug Design (Blackwell Press)

Senior Editor (2006-2012)

Publications (Over 65 peer reviewed papers and one book and multiple patents)